The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying these cells in peripheral blood.
Histologically documented diagnosis of metastatic/locally advanced melanoma, hormone-refractory breast cancer, RCC and UC, SCCHN, SCC or NSCLC, stage III resectable NSCLC will also be included
Will and ability to comply with the protocol
Willingness and ability to provide an adequate archival Formalin-Fixed Paraffin-Embedded (FFPE) tumor sample available for exploratory biomarker analysis
Age from 18 to 90 years at the time of recruitment
Known history of HIV infection
Serious neurological or psychiatric disorders
Pregnancy or lactation
Inability or unwillingness of participant to give written informed consent
6
Treatment groupsSee each treatment group below.